G:NYSEGenpact Limited Analysis
Data as of 2026-09-05 - not real-time
$37.32
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind Genpact Limited is neutral at $37.32, with no clear ordering between short and long averages. It has gained 19.4% over the past 30 days. Relative strength is 60.0 — approaching overbought — and the MACD signal is bearish. Watch $33.00 as support and $38.85 as the nearer resistance level.
The shares look undervalued, trading on 11.1 times earnings below a sector average of 33.2. Sell-side targets cluster 13.0% above the current quote. Revenue is growing at 7.1% on a 11.1% profit margin. The 1.97% dividend yield looks covered by current payout levels.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 41.1%, a beta of 0.13 and a maximum drawdown of 43.3%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
The shares look undervalued, trading on 11.1 times earnings below a sector average of 33.2. Sell-side targets cluster 13.0% above the current quote. Revenue is growing at 7.1% on a 11.1% profit margin. The 1.97% dividend yield looks covered by current payout levels.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 41.1%, a beta of 0.13 and a maximum drawdown of 43.3%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
Top Market Events
Why Genpact stock is back in focus after its latest earnings Genpact G has returned to the spotlight after reporting...Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in...Business transformation services company Genpact NYSE:G announced better-than-expected revenue in Q2 CY2026, with sales...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 37.60
- MACD momentum is negative
- 30-day price change of +19.4%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 11.1 versus sector average of 33.2
- Trading below the 200-day average of 37.60
- Analyst targets imply +13.0% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 11.1 versus sector average of 33.2
- Analyst targets imply +13.0% versus the current price
- Return on equity of 22.4%
Key Metrics & Analysis
Financial Health
Revenue Growth7.10%
Profit Margin11.10%
P/E Ratio11.1
ROE22.45%
ROA9.18%
Debt/Equity54.31
P/B Ratio2.4
Op. Cash Flow$644.0M
Free Cash Flow$479.4M
Industry P/E33.2
Technical Analysis
TrendNeutral
RSI60.0
Support$33.00
Resistance$38.85
MA 20$36.25
MA 50$33.37
MA 200$37.60
MACDBearish
VolumeDecreasing
Fear & Greed Index95.48
Valuation
Fair Value$43.50
Target Price$42.18
Upside/Downside13.03%
GradeUndervalued
TypeBlend
Dividend Yield1.97%
Risk Assessment
Beta0.13
Volatility41.11%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.